Pathios Therapeutics, an Oxford, UK-based biotech company focused on the development of therapies for cancer, raised $25M in first closed of Series B funding.
Backers included Bristol Myers Squibb, and existing investors including Canaan and Brandon Capital.
The company intends to use the funds for the continued development of its approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases.
Led by Tom McCarthy Ph.D., co-founder and executive chair, and Stuart Hughes, Ph.D., chief executive officer, Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. The company is focused on developing small molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to counteract the GPR65 mediated immunosuppressive polarization of immune cells, including tumor associated macrophages, that is triggered by an acidic tumour microenvironment present in most cancers.
FinSMEs
19/04/2024